ArticleDrug delivery and translational research2019
Protective effect of surface-modified berberine nanoparticles against LPS-induced neurodegenerative changes: a preclinical study.
Article in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients.Contrast media & molecular imaging · 2022Trial
- Neuroprotective mechanisms of nutraceutical berberine: Preclinical evidence and future perspectives.Advances in neurotoxicology · 2026Article
- Nanomedicine-enabled neuroprotection: therapeutic role of berberine in neurodegenerative diseases.Molecular biology reports · 2025Review
- Berberine-loaded iron oxide nanoparticles alleviate cuprizone-induced astrocytic reactivity in a rat model of multiple sclerosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Article
- In vitro and in vivo studies of selenium nanoparticles coated bacterial polysaccharide as anti-lung cancer agents.Microbial cell factories · 2024Article
- Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases.Biomimetics (Basel, Switzerland) · 2024Review
- Chitosan Nanoparticles Alleviated the Adverse Effects of Sildenafil on the Oxidative Stress Markers and Antioxidant Enzyme Activities in Rats.Oxidative medicine and cellular longevity · 2023Article
- Nanocarrier-Based Drug Delivery to Brain: Interventions of Surface Modification.Current neuropharmacology · 2023Review
- The Neuroprotective and Antioxidant Effects of Nanocurcumin Oral Suspension against Lipopolysaccharide-Induced Cortical Neurotoxicity in Rats.Biomedicines · 2022Article
- Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity.Journal of pharmaceutical investigation · 2021Article
- Therapeutic Potential of Phytoconstituents in Management of Alzheimer's Disease.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Solubility and Stability Advantages of a New Cocrystal of Berberine Chloride with Fumaric Acid.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR) exerts documented protection against neurodegenerative disorders. However, data on the effect of nano-encapsulation on the neuroprotective effect of BBR are lacking. We investigated the effect of BBR loading into chitosan (CS) nanoparticles (NPs) and their surface modification with Tween 80 (T80), polyethylene glycol 4000 (PEG), and miltefosine (MFS) against lipopolysaccharide (LPS)-induced neurodegenerative changes in addition to hepatotoxicity in rats. BBR-NPs were prepared by ionic gelation and characterized for morphology by transmission electron microscopy (TEM), colloidal properties, and entrapment efficiency (EE%). The neuroprotective and hepatoprotective effects of a 14-day pretreatment with four BBR-NPs formulations (4 mg/kg BBR/day) by intraperitoneal (i.p.) injection were challenged by a single i.p. 4 mg/kg dose of LPS on the fifteenth day. Neuroprotective efficacy and potential toxicity of BBR-NPs relative to BBR solution were assessed biochemically and histopathologically. One-way ANOVA followed by Tukey's comparison test was used for statistical analysis. CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features. Similar to the prophylactic and treatment efficacy of NPs for brain delivery, safety of these nanostructures and their individual formulation components warrants due research attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.